March 2019 FDA Recall Drug by H J Harkins Company Inc Dba Pharma Pac
D-1083-2019 - CGMP Deviations

This Class II drug recall was voluntarily initiated by H J Harkins Company Inc Dba Pharma Pac on March 4, 2019 for the product Drug. The FDA reported the reason for recall as cgmp deviations. The product was distributed in Product was distributed to a physician's office in California. and the recall is currently terminated.

Recall Number: D-1083-2019

Reason for Recall
CGMP Deviations:Traces amounts of N-Nitroso N-Methyl 4- amino butyric acid (NMBA) impurity found in Active Pharmaceutical Ingredient (API).
Initiated
03-04-2019
Reported
04-17-2019
Quantity
300 tablets

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
H J Harkins Company Inc dba Pharma Pac
Product was distributed to a physician's office in California.
Losartan Potassium 100 mg Tablets # 30 Losartan potassium tablets USP, 100 mg are white to off white, film coated, tear drop shaped tablets, debossed with "H" on one side and "145" on the other side.

Batch or Lot Expiration Information

Lot# Pharma Pac NDC: 76519-1033-03, Pharma Pac
Lot# LTO00EW, Exp. 11/19, MFG NDC 31722-0702-30, MFG
Lot# LOP17087, Exp. 11/2019.